Dr. Lara on the Potential Role of IDO Inhibitors in the Treatment of RCC

Partner | Cancer Centers | <b>UC Davis</b>

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).

The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).